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The analysis of sewage for the residues of commonly used illicit drugs has successfully been 
applied as a suitable approach for estimating community illicit drug use. The drug market is 
increasingly dynamic with new substances continually being marketed for recreational 
purposes. In this study ultra-high pressure liquid chromatography coupled to tandem mass 
spectrometry (UHPLC-MS/MS) was used to simultaneously and quantitatively detect the 
exogenous biomarkers of new classes of recreational drugs in sewage collected from three 
different Norwegian cities (Oslo, Bergen, Hamar). The samples were screened for the 
presence of khat (d-norpseudoephedrine and cathinone), mephedrone, pseudoephedrine, 7-
aminoflunitrazepam, para-methoxyamphetamine (PMA), para-methoxy-N-
methylamphetamine (PMMA) and a selection of urinary metabolites of synthetic 
cannabinoids collectively termed ´Spice´ (5-3-1-naphthoyl-1H-indol-1-yl-pentanoic acid 
(JWH 018 N-pentanoic acid), 1-5-hydroxypentyl-1H-indol-3-ylnaphthalen-1-yl-methanone 
(JWH 018 N-5-hydroxypentyl), 4-3-1-naphthoyl-1H-indol-1-yl-butanoic acid (JWH 073 N-
butanoic acid), 1-4-hydroxybutyl-1H-indol-3-ylnaphthalen-1-yl-methanone (JWH 073 N-4-
hydroxybutyl), 1-5-hydroxypentyl-1H-indol-3-yl4-methylnaphthalen-1-yl-methanone (JWH 
122 N-5-hydroxypentyl), 1-5-fluoro-4-hydroxypentyl-1H-indol-3-ylnaphthalen-1-
ylmethanone (AM2201 N-4-hydroxypentyl), and 1-5-hydroxypentyl-1H-indol-3-yl4-
methoxyphenyl-methanone (RCS-4 N-5-hydroxypentyl)). Limits of detection were 1 ng/L for 
amphetamine like compounds and 5 ng/L for the metabolites of synthetic cannabinoids while 
the limits of quantification were 3 and 15 ng/L respectively.  Three of the fourteen selected 
biomarkers (cathine, pseudoephedrine and the synthetic cannabinoid metabolite JWH-018 N-
5-hydroxypentyl) were detected in sewage, alongside the illicit drugs (and/or metabolites) 
typically found in sewage (cocaine, benzoylecognine, methamphetamine, MDMA and THC-
COOH). The khat biomarker d-norpseudoephedrine was detected in Oslo sewage at a mean 
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concentration of 93 ng/L that represents a daily load of 54 mg/day/1000 inhabitants. 
Pseudoephedrine was present at mean concentrations of between 27 and 67 ng/L representing 
normalised daily loads of between 10 (Hamar) and 24 mg/day/1000 inhabitants (Bergen). The 
daily normalised loads of JWH-018 N-5-hydroxypentyl were between 49 (Oslo) and 62 
mg/day/1000 inhabitants (Hamar). For the first time this study demonstrates that sewage 
biomarker analysis can be applied to evaluate not only the use the traditional illicit drugs 
(cocaine, cannabis and amphetamines), but also the use of certain new synthetic drugs. 
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Introduction 
The estimation and comparison of community drug use through the analysis of selected drug 
biomarkers in sewage is rapidly becoming established as an effective monitoring tool. [1] The 
approach, akin to analysing a community urine sample, has been applied on a local [2], 
national, [3] and international scale [1] to take the quantitative measurements of drug 
biomarkers in sewage and use them to estimate drug use within a defined population. Over the 
past few years the approach has seen significant refinement as well as an increased awareness 
of its uncertainties [4,5,6,7,8,9]. This includes improvements in sample collection and the factors 
that affect the representativeness of a sample [4,5], the fate of biomarkers between the point of 
excretion and sampling [6] , the stability of biomarkers post-sampling [7,9] and those factors 
that most influence the estimation itself. [10, 11] The popularity of sewage analysis for 
estimating drug use has resulted in its wider application being proposed for example for the 
measurement biomarkers relating to community health [12,13] (termed BIOSCIM [13]). One 
obvious further application of the approach is to see whether other classes of drugs can be 
detected; for example so-called ‘legal highs’ that contain new psychoactive substances. These 
‘new’ compounds are made to simulate the effects of common illicit drugs, sometimes by 
simply adding or changing a functional group on the original drug molecule. Very little is 
known about the use and prevalence of these drugs and their control status varies from 
country to country (see www.emcdda.europa.eu/drug-profiles for most recent status). 
 
New psychoactive drugs were detected in the European Union (EU) at a rate of around one 
per week in 2011 (49 new substances)[14] and are typically detected through the EUs Early 
Warning System. Typically sold online or through specialist stores the new substances are 
exclusively synthetic and typically dominated by synthetic cannabinoids and cathinones. 
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Synthetic cannabinoid (cannabinoid receptor agonists) based products, also known as ´Spice´, 
often contain a mixture of different compounds with new analogues being introduced as 
substances become restricted. Synthetic cannabinoids undergo extensive metabolism within 
the body, leading to very low levels of the parent compound present in urine,[15] therefore for 
sewage analysis the known urinary metabolites of a range of synthetic cannabinoid analogues 
were selected as biomarkers (JWH-018 N-Pentanoic Acid, JWH-018 N-5-hydroxypentyl 
(from the parent JWH-018), JWH 073 N-butanoic acid, JWH-073 N-4-hydroxybutyl (from 
the parent JWH-073), JWH 122 N-5-hydroxypentyl (from the parent JWH-122), AM2201 N-
4-hydroxybutyl (from the parent AM2201) and RCS-4 N-5-hydroxypentyl (from the parent 
RCS-4) (Table 1).  
 
Khat (Catha edulis) is a plant grown in Africa that is known to contain d-norpseudoephedrine 
(NPE) and cathinone that are released into the saliva upon chewing. [16] NPE and cathinone 
are very similar in structure to amphetamine with similar pharmacological effects on the 
central nervous system. [17] Khat chewing is a traditional practice in certain East African 
countries with its use in Europe being linked to immigrants from Somalia, Ethiopia, Kenya 
and Yemen. 
[17] Synthetic cathinones are the β-keto (βk) analogues of a corresponding 
phenethylamine. Mephedrone (4-methylmethcathinone, 4-MMC) is a synthetic cathinone that 
is increasingly occurring on the drug market and was therefore included in this study. 
[17]
 
Para-methoxyamphetamine (PMA) and para-methoxy-N-methylamphetamine (PMMA) are 
synthetic derivatives of methamphetamine that are chemically analogous to MDMA (ecstasy). 
[17] Flunitrazepam (Rohypnol, FM2) pseudoephedrine (PEP) are pharmaceuticals that have 
non-medical uses that have resulted in their tight control in certain countries. [17] For example, 
FM2 is often used as a recreational drug while PEP is a stimulant listed on the World Anti-
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Doping Agency list of prohibited substances. 
 
The aim of this work was for the first time to develop and validate a rapid and sensitive 
targeted method for simultaneous quantitative determination of biomarkers specific to these 
drugs in raw sewage with the goal of evaluating whether sewage analysis may be a potential 
tool for gathering improved information on the prevalence of new illicit substances.  
 
Experimental 
Chemicals and materials 
5-3-1-Naphthoyl-1H-indol-1-yl-pentanoic acid (JWH 018 N-pentanoic acid), 1-5-
hydroxypentyl-1H-indol-3-ylnaphthalen-1-yl-methanone (JWH 018 N-5-hydroxypentyl), 4-3-
1-naphthoyl-1H-indol-1-yl-butanoic acid (JWH 073 N-butanoic acid), 1-4-hydroxybutyl-1H-
indol-3-ylnaphthalen-1-yl-methanone (JWH 073 N-4-hydroxybutyl), 1-5-hydroxypentyl-1H-
indol-3-yl4-methylnaphthalen-1-yl-methanone (JWH 122 N-5-hydroxypentyl), 1-5-fluoro-4-
hydroxypentyl-1H-indol-3-ylnaphthalen-1-ylmethanone (AM2201 N-4-hydroxypentyl), 1-5-
hydroxypentyl-1H-indol-3-yl4-methoxyphenyl-methanone (RCS-4 N-5-hydroxypentyl), para-
methoxyamphetamine (PMA), para-Methoxy-N-methylamphetamine (PMMA) were obtained 
from Chiron (Trondheim, Norway) in solutions of methanol or acetonitrile. Methanol 
solutions of 4-4MMC, NPE, benzoylethanamine (2S-cathinone), 7-aminoflunitrazepam (7-
aminoFM2), mephedrone-d3, 7 aminoflunitrazepam-d7, Methamphetamine-d5 and 11-Nor-9-
Carboxy-delta9-THC-d3 were obtained from Nerliens Meszansky (Norway). EP and PEP were 
purchased from Sigma-Aldrich (Norway). The purity of all standards was 99%.  
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Sample collection 
Sewage samples (2 x 1L) were collected from the Norwegian cities of Oslo (population 
557,000, mean sewer retention time 7h), Hamar (population 55,000, mean sewer retention 
time <3h) and Bergen (population 71,000, mean sewer retention time <3h), representing a 
weekend (Friday to Monday morning) in July 2012 (13th-15th). The samples were 3-day 
volume proportional composite made-up of a blended mix of inlet sewage. These were 
shipped to the laboratory and stored -20ºC. An additional 3 litres of sample was collected 
from Oslo and stored in the fridge for use in developing the method. 
 
Sample extraction 
Defrosted sewage samples (500 mL) and Milli-Q water (100 mL) were spiked with deuterated 
standards and the pH adjusted to 3 using acetic acid. The final concentration for each internal 
standard was 100 ng/L. Solid phase extraction (SPE) was performed using Oasis MCX 
cartridges (Waters, USA). These were conditioned using methanol (MeOH) (12 mL) followed 
by acidified Milli-Q water (0.1% acetic acid at pH 3; 12 mL). Samples were drawn through 
under vacuum and the cartridges washed using acidified water (0.1% acetic acid at pH 3; 12 
mL). Cartridges were then vacuum dried for 50 minutes. The analytes were eluted using 2% 
ammonium hydroxide in MeOH (12 mL) and acetonitrile (6 mL), evaporated to dryness at 40 
ºC under a gentle stream of nitrogen and reconstructed in a solution of acetonitrile, methanol 
and Milli-Q water (2 mL). This was then centrifuged at 10,000 g for 10 mins and 7µl injected 
into the UHPLC-MS/MS system.  
 
Instrumentation 
A Waters Acquity Ultra performance LC system coupled to a Waters Quattro Premier XE 
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mass spectrometer (Waters, USA) was used. Separation was performed using an Acquity 
UPLC BEH C8 column (1.7µm particle size). Gradient elution was performed at a constant 
flow rate of 0.6 mL/min, using NH4AC 10 mM and 0.1 % acetic acid in water (Solvent A) and 
NH4AC 10 mM and 0.1 % acetic acid in MeOH (Solvent B) as the mobile phase. The gradient 
used was as follows: Start at 0 minutes with 1 % Solvent B and 99 % Solvent A, held for 1 
minute. 1-3 minutes linear rate to 35 % B, 3-5 minutes linear rate to 80 % B, 5.10-6.10 linear 
rate to 99 % B, 6.10-7 minutes return to initial conditions; 1 % B. Positive ionisation 
electrospray was used with nitrogen as the cone (flow 55 L/h) and desolvation gas (flow 800 
L/h). The capillary voltage was set to 320 V, source temperature 100 ºC, desolvation 
temperature 450 ºC and dwell times of 0.01 s per transition were used. All data was acquired 
and processed using MassLynx v 4.1 software. The analyte specific MS parameters are 
presented in Table 2.  
 
Quantification and method validation  
Data acquisition was performed in MRM mode with the protonated molecular ion of each 
compound used as the precursor ion. Where possible two product ions with the greatest 
abundance were chosen for further confirmation (Table 2). The linearity of the method was 
studied by analysing standard solution in triplicate at six different concentrations. For the 
synthetic cannabinoids this ranged from 500 ng/mL to 15 ng/mL and for all other compounds 
this ranged from 50 ng/mL to around 1.6 ng/mL. Internal standard was spiked in at 100 ng/mL 
for ratio purposes. Linearity was assumed when the correlation coefficient (R2) was > 0.99, 
based on the ratio of analyte peak area and internal standard peak area at each concentration. 
The limit of quantification (LOQ) was taken as the lowest concentration level for which the 
method was fully validated using spiked samples with satisfactory recovery (31-71%; Table 
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S1) and precision (Table S2). The limit of detection (LOD) was defined as the lowest 
concentration that the analytical process can differentiate between background levels. This 
was found with a signal to noise ratio of 3 to 1 with the lowest concentration that could still 
be detected. Precision was expressed as the repeatability of the method in terms of RSD. The 
% RSD value of the peak areas given determined the precision of the method when screening 
for each compound. Accuracy was tested by analysing the % absolute recovery from samples 
that had been spiked with a known amount and passed through the SPE method. All recovery 
experiments were performed in quintuplicate for both Milli Q and waste-water. 
 
Analyte stability 
The stability of the selected biomarkers in sewage was considered by spiking 200 ng/mL of 
each cannabinoid and 100 ng/mL of each of the other compounds into sewage (pH 7.2) in a 
500 mL clean glass flask kept at room temperature (21˚C). An aliquot (500 µL) was taken at 
the following time intervals (0, 15, 30, 60, 120, 240, 360, 1440, and 2880 minutes) and 
injected into the UHPLC-MS. A “blank” sample was also tested alongside this, and any 
positive measurement was subtracted from the spiked sample. 
 
Results and Discussion 
Method validation 
The method was validated for both Milli Q water and raw sewage prior to its application. 
Analyte stability, linearity, precision, accuracy, limit of quantification (LOQ) and limit if 
detection (LOD) were evaluated for each analyte. The MS detector showed good linearity 
R2>0.99 for all compounds selected in this method as determined by a six-point calibration 
curve (synthetic cannabinoids 15.6 to 500 ng/L, all other drugs  1.6 to 50 ng/L). The LOD 
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was estimated to be 1 ng/L (5 ng/L for cannabinoids) and LOQ was 3 ng/L (15 ng/L for 
cannabinoids). The mean recovery for the synthetic cannabinoids was between 31 and 71%, 
and 31 and 58% for the amphetamine-like drugs with RSDs of between 5 and 40% (Table S1).   
The stability test showed that the selected amphetamine-like substances were stable in sewage 
with typically between 70 and 84% remaining after 24h (Table S2). Mephedrone was however 
less stable with only 63% present following 24h at room temperature, suggesting that its 
stability should be carefully considered when storing samples and when calculating sewage 
loads, especially in systems with long in-sewer retention times. Some of the synthetic 
cannabinoid metabolites were unstable in sewage over 24h at room temperature, namely JWH 
122 n-5-hydroxypentyl, AMM2201 n-4-hydroxypentyl, RCS-4 N-5-hydroxypentyl and JWH 
073 N-4-hydroxybutyl (Table S2). This suggests that these synthetic cannabinoid metabolites 
do not make good sewage biomarkers since they will degrade between the point of excretion 
and sewage sample collection. JWH 018 n-pentanoic acid, JWH 073 N-butanoic acid and 
JWH018 N-5-hydroxypentyl were stable and are therefore suitable for consideration as 
sewage biomarkers. 
 
Occurrence in sewage 
Of the 14 new compounds targeted in this screening study only three were detected in the 
sewage samples analysed. The sample collected from Oslo tested positive for 
ephedrine/pseudoephedrine, JWH 018 N-5-hydroxypentyl and NPE, while PEP and JWH 018 
N-5-hydroxypentyl were detected in Bergen and Hamar (Table 3). The same samples all 
contained COC, BE, METH and THC-COOH (Table 3). MDMA was only detected in Oslo.  
Mean concentrations of JWH 018-N-hydroxpentyl were between 83 and 160 ng/L, normalised 
to population equivalents loads of between 49 and 62 mg/day/1000 inhabitants. The presence 
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of JWH 018-N-hydroxpentyl, a urinary metabolite of one of the most common synthetic 
cannabinoids JWH 018, [18] in samples collected from all three cities suggests that its use is 
widespread in Norway. The samples from Hamar also indicated the presence of another 
synthetic cannabinoid, JWH 122 but at concentrations below the LOQ of the method. An 
initial report into the occurrence of synthetic cannabinoid receptor agonists identified JWH 
018 as one of the most frequently occurring, however not present at the time in Norway. [14] 
 
NPE, a sewage biomarker for khat, was only detected in Oslo that corresponded to a mean 
population normalised load of 54 mg/day/1000 inhabitants. The mass chromatogram for NPE 
contained a number of co-eluting and/or unresolved peaks (Figure SI1) that may correspond 
to glucuronide or sulphate metabolites of NPE or possibly phenylpropanolamine (a 
stereoisomer of cathine and available as the prescription medicine Rinexin). [19] The absence 
of the other khat biomarker cathinone is expected because only around 2% of the compound 
is excreted unchanged in urine [20] (the majority is excreted as NPE) and the level of use 
would have to be very large. NPE is also a metabolite of PEP with ~1% transformed via N-
demethylation. [21] and therefore it is possible that a small amount of the NPE signal may be 
from the use of PEP.  
 
PEP and ephedrine (EP) are isomers and our method does not chromatographically separate 
them, however this is possible by using a specific chiral column. Therefore when interpreting 
the PEP signal it is necessary to also include EP. PEP is not approved for use in Norway, and 
EP is very strictly controlled, yet both compounds were detected in all three locations that 
suggest widespread use of this controlled substance.  Unfortunately this was not possible as 
part of this study.  EP, a prescription only medication in Norway is rarely used and records for 
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2011[19] show a total annual usage of only 103 doses per thousand inhabitants in Oslo, 92 
doses/1000 inhabitants in Bergen and 59 doses/1000 inhabitants in Hamar. [19] The defined 
daily dose (DDD) for EP is 50 mg, so prescription records would therefore suggest a 
consumption rate of 8-14 mg/day/1000 inhabitants in all three locations. Approximately half 
the initial dose of EP is excreted unchanged in urine [21,22] so sewage loads of this compound 
from prescription only medication will be expected to be of the order of 5-10 mg/day/1000 
inhabitants. The measured load in Hamar (10.6 mg/day/1000 inhabitants) is likely therefore to 
be solely due to legal prescription use. Loads in Oslo (18 mg/day/1000 inhabitants) and 
Bergen (24 mg/day/1000 inhabitants) are however in excess of that which would be expected 
from prescription use, and therefore indicate the possibility of some illicit consumption. These 
are the first reported measurements of these drugs through sewage biomarker analysis 
therefore there are no data with which to compare with.  
 
The population-normalised load for cocaine (COC) and its main metabolite BE, together with 
METH and THC-COOH were greatest is Oslo. This is unsurprising since Oslo is a capital city 
and the largest city in Norway. Estimation of COC use through the transformation of the 
normalised mean benzoylecognine loads using the median excretion value of 38% and a 
correction factor of 2.77 of BE excretion 
[23] 
shows that up to five-times as much cocaine was 
used in Oslo (146 mg COC/day/1000 inhabitants) compared to Hamar (33 mg COC/day/1000 
inhabitants) and three-times as much as Bergen (48 mg COC/day/1000 inhabitants). When 
compared to previous studies performed in Oslo these data are within the same range as 
previously measured (100 - 900 mg COC/day/1000 inhabitants). 
[1]
 The lower level of use in 
less urbanized areas within a country has previously been observed 
[1,3]
 and possibly reflects 
the greater availability of drugs within a large urban area. The METH load relative to 
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population size was again higher in Oslo (117 mg METH/day/1000 inhabitants) compared to 
Bergen (70 mg METH/day/1000 inhabitants) and Hamar (39 mg METH/day/1000 
inhabitants). When compared to other European cities there values are relatively high with 
only previous reports from Oslo, Helsinki, Turku (both in Finland) and Budweis (Czech 
Republic) being higher.
[1]
 The comparatively high levels of METH determined in Norwegian 
sewage are reflected in the statistics relating to the size and frequency of seizures of METH in 
the Nordic region. 
[24]
 The highest measured per capita THC-COOH load was determined in 
Oslo (59 mg THC-COOH/day/1000 inhabitants) with lower yet similar levels estimated for 
Bergen and Hamar (39 and 35 mg THC-COOH/day/1000 inhabitants). The per capita THC-
COOH loads are comparable with the range that has previously been reported for European 
cities,[1] excluding Amsterdam (14-124 mg THC-COOH/day/1000 inhabitants). MDMA is 
rarely detected in Oslo due to its low level of use and the concentrations measured in the 
samples collected from the three cities reflect this. 
For the first time we have demonstrated that targeted sewage analysis can be used to evaluate 
the use of new synthetic drugs on a community level, however it is clear that they offer a 
greater challenge than for example cocaine or methamphetamine. The challenge with new 
synthetic drugs, and in particular synthetic cathinones and cannabinoids, is that there are 
numerous analogues available and new drugs are constantly being synthesised. A successful 
sewage based approach for determining the use of a new drug in society is dependent on the 
identification of the correct biomarker based on whatever pharmacokinetic data are available. 
Secondly the prevalence of use of the drug needs to be sufficiently high to generate a large 
enough concentration of the chosen biomarker in sewage that can then allow for detection and 
analysis. It is desirable that a selected biomarker is preferentially present in the aqueous phase 
and does not excessively partition onto solids. The presence of the selected biomarker(s) at a 
 14 
 
sufficiently high concentration is also dependent on the stability of the biomarker in sewage; 
labile compounds will simply degrade before they reach the point of sampling. This appears 
to be the case for a number of synthetic cannabinoid metabolites.  
 
The measurement of the use of synthetic cannabinoids by sewage analysis is therefore 
challenging since these compounds are often sold in mixtures, and it is possible that the level 
of one particular biomarker may never be sufficiently high to allow for analysis. One solution 
option is to try and get a larger more integrated sample, for example by using passive 
sampling techniques such as the polar organic compound integrative sampler (POCIS). [5] 
Since a targeted analytical approach such as the one adopted here is reliant on the availability 
of authentic reference standards then another option may be a non-target approach using high 
resolution MS. A non-target approach would however require the identification of suitable 
biomarkers to allow a retro-analytical approach to be used since searching for the parent drug 
offers no guarantee of its presence in urine and subsequently sewage. Since the majority of 
(recently identified) new synthetic drugs are cannabinoid or cathinone related then it may be 
possible to develop or apply transformation/metabolism models based upon the 
pharmacokinetics of known drugs to provide valuable information on what is likely to occur 
in sewage. Therefore it is clear that new synthetic drugs offer a number of challenges over 
those that have already been overcome for traditional illicit drugs such as cocaine and 
amphetamine but that sewage analysis is an additional tool that can be used to gauge the use 
and emergence of such drugs on a community level. 
  
Conclusion 
A method has been successfully developed and applied to screen for the presence of new 
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classes of illicit drugs, including synthetic cannabinoids and amphetamine like compounds, in 
sewage. Our initial study suggests that JWH 018 N-5-hydroxypentyl and JWH 073 N-
butanoic acid are suitable sewage biomarkers for their respective parent synthetic 
cannabinoids, whilst NPE has the potential to be a sewage biomarker for khat. Further work is 
needed for a number of the other compounds evaluated, however it is clear that the following 
proposed sewage biomarkers are not suitable due to being rapidly transformed in sewage; 
JWH 122 n-5-hydroxypentyl, AM2201 n-4-hydroxylpentyl, RCS-4 N-5-hydroxypentyl, JWH 
073 N-4-hydroxybutyl. Evaluation of the technique at three Norwegian cities showed that the 
synthetic cannabinoid JWH 018 and ephedrine/pseudoephedrine are used in all three cities, 
along with the traditional drugs such as COC, METH and THC-COOH. The use of khat was 
only detected in Oslo.   
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Table 1. Structural and molecular details of the selected drugs 
 Drug  Target biomarker(s) Chemical structure 
Khat 
 
Cathinone 
 
 
Norpseudoephedrine  
(NPE) 
 
Pseudoephedrine (PEP) PEP 
 
Mephedrone 
 (4-methylmethcathinone, 
4-MMC) 
Mephedrone 
 
Flunitrazepam 7-aminoflunitrazepam 
(7-aminoFM2) 
 
NH2
O
OH
CH3
NH2
OH
NH
N
O
H
NH2
N
O
N F
 19 
 
Synthetic cannabinoids 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RCS-4 N-5-
hydroxypentyl 
 
 
 
 
JWH 122 N-5- 
hydroxypentyl 
  
AM 2201 N-4-
hydroxypentyl 
 
JWH-018 N-pentanoic 
acid 
  
 
 
JWH 018 N-5- 
hydroxypentyl 
 
 
JWH 073 N-butanoic 
acid 
 
OH
O
N
O
COOH
O
N
 20 
 
JWH 073 N-4-
hydroxybutyl 
 
 
 
para-Methoxyamphetamine 
(PMA) 
PMA 
 
 
 
para-Methoxy-N-
methylamphetamine 
(PMMA) 
PMMA  
 
 
OH
O
N
NH2
O
O
N
 21 
 
Table 2 Compound parameters, showing transitions for reporter and qualifier ions. 
Compound tr 
(min) 
Precursor 
ion (m/z) 
[M+H]+ 
Cone 
voltage 
(V) 
CEa (eV) Product Ion (m/z) 
Mephedrone 2.06 178 25 20 
12 
145 
160  
7-aminoflunitrazepam 2.9 284 30 25 135 
Norpseduoephedrine  1.27 152 25 15 
10 
117 
134  
Cathinone 1.28 150 20 15 132  
Pseudoephedrine 1.46 166 20 15 117  
148  
PMA 1.81 166 15 10 
15 
149 
121 
PMMA 1.9 180 20 15 
10 
120  
149 
JWH-018 N-pentanoic acid 3.87 372 40 25 155 
JWH 018 N-(5 
hydroxypentyl) 
3.97 358 35 20 
35 
155 
144 
JWH 122 N-(5 
hydroxypentyl) 
4.23 372 40 25 169 
230 
AM 2201 N-(4- 3.98 376 45 25 155 
 22 
 
hydroxypentyl) 
RCS-4 N-(5-
hydroxypentyl) 
3.85 338 35 20 134 
JWH 073-N-butanoic acid 4.08 358 40 20 155 
JWH 073 N-(4-
hydroxybutyl) 
3.95 344 40 20 
20 
127 
155 
7-aminoflunitrazepam-d7 
Mephedrone-d3 
Methamphetamine-d5 
THC-11-oic acid-d3 
2.87 
 
2.05 
1.74 
4.73 
291 
 
181 
155 
348 
45 
 
25 
25 
35 
35 
 
20 
15 
30 
138 
 
147 
92 
196 
a CE : collision energy.  
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Table 3 Mean concentration of selected drug biomarkers in sewage collected from Oslo, Hamar and Bergen (Norway) in July 2012.  
Biomarker Oslo Hamar Bergen 
Mean 
concentration 
(ng/L) 
Normalised Load 
(mg/day/1000 
inhabitants)a 
Mean 
concentration 
(ng/L) 
Normalised Load 
(mg/day/1000 
inhabitants)a 
Mean 
concentration 
(ng/L) 
Normalised Load 
(mg/day/1000 
inhabitants)a 
JWH 018 N-5-
hydroxypentyl 
83.4 48.9 157 62.0 160 56.1 
Norpseuoephedrine 92.5  54.3 <3 0.6e <3 0.5e 
Pseudoephedrine 30.8 18.1 26.8 10.6 67.0 23.5 
Cocaineb 25 
 
14.7 
23-34c 
2.5 1.0 15 5.3 
Benzoylecgonineb 90 
 
52.8 
52-105c 
30 11.8 50 17.5 
 24 
 
Methamphetamineb 200 117.3 
245-383c 
100 39.39 200 70.04 
THC-COOHb 100d 58.7 
n/ac 
100d 39.4 100d 35.0 
MDMAb 10d 
 
5.9 
n/ac 
n/a - n/a - 
 
a Sewer catchment population data provided by STW operators based upon census data. 
b estimated concentrations and normalised loads 
c range of previous loads measured  in Oslo [16,18] 
d Semi-quantitative results based on single-point calibration curves derived from a spike of deuterated MDMA and THC-COOH into each 
sewage sample 
e Calculated from a concentration of LOQ/2. 
n/a: data not available. 
